BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15149738)

  • 1. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
    Wang J; Eltoum IE; Lamartiniere CA
    Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
    Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
    Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
    Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A
    Cancer Res; 2001 Sep; 61(18):6777-82. PubMed ID: 11559550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
    Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
    Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
    Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H
    Cancer Res; 2004 Dec; 64(23):8715-22. PubMed ID: 15574782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
    Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells.
    Pandini G; Genua M; Frasca F; Squatrito S; Vigneri R; Belfiore A
    Cancer Res; 2007 Sep; 67(18):8932-41. PubMed ID: 17875736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.
    Sutherland BW; Knoblaugh SE; Kaplan-Lefko PJ; Wang F; Holzenberger M; Greenberg NM
    Cancer Res; 2008 May; 68(9):3495-504. PubMed ID: 18451178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
    Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype.
    El Touny LH; Banerjee PP
    Carcinogenesis; 2007 Aug; 28(8):1710-7. PubMed ID: 17468512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells.
    Lazarevic B; Karlsen SJ; Saatcioglu F
    Oncol Rep; 2008 May; 19(5):1231-5. PubMed ID: 18425381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma.
    Hagan M; Yacoub A; Dent P
    Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.